Introduction: Angiotensin-converting enzyme inhibitor (ACEi)-induced angioedema is a serious emergency that can cause life-threatening symptoms and death if not treated promptly. Potential treatment options for ACEi-induced angioedema include medications with limited evidence for use in this patient population. The purpose of this study was to evaluate the use, clinical efficacy, and angioedema-related medication costs of C1 esterase inhibitor (C1EI) for ACEi-induced angioedema.
Methods: This was a retrospective, propensity-matched cohort study comparing patients who received C1EI to those who did not receive C1EI for ACEi-induced angioedema. The primary outcome of interest was comparing the proportion of patients who required intubation secondary to ACEi-induced angioedema. Secondary endpoints of interest were also included.
Results: After propensity score matching, 22 patients were stratified into both the non-C1EI group and C1EI group, respectively. There was no difference between the groups with respect to the proportion of intubation (13.6% in the C1EI group vs. 9.1% in the non-C1EI group, p > 0.999). Mean cost of angioedema-related medication therapy was higher in the C1EI group compared to the non-C1EI group [$8758.95 (± $2959.30) vs. $15.91 (± $7.32), p < 0.001].
Conclusions: In this retrospective cohort study, the use of C1EI for ACEi-induced angioedema did not demonstrate improved outcomes with respect to intubation and resulted in increased costs. Larger, multicenter, prospective studies are needed to further validate the results of this study and to provide more clarity on the role of C1EI therapy in ACEi-induced angioedema.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajem.2021.05.036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disposition of emergency department patients presenting with angiotensin-converting enzyme inhibitor-induced angioedema.
Int J Emerg Med
January 2025
Department of Emergency Medicine, Wake Forest Baptist Medical Center, 475 Vine Street, Winston-Salem, NC, 27101, USA.
Background: Angiotensin-converting enzyme inhibitors (ACEI) are the most common cause of drug-induced angioedema in the United States. Our primary objective was to provide descriptive evidence regarding emergency department (ED) disposition of ACEI-induced angioedema patients. Our secondary objective was to evaluate unique patterns in those with ACEI-induced angioedema at a tertiary referral center, including demographics, details of those requiring intubation, length of inpatient stay, and allergy documentation.
View Article and Find Full Text PDFUnilateral tongue swelling: an unusual presentation of angiotensin-converting enzyme inhibitor-related angioedema.
BMJ Case Rep
August 2024
Emergency Medicine, Karl Bremer Hospital, Cape Town, Western Cape, South Africa.
Article Synopsis
- * A case report highlights a male in his 60s who experienced unusual swelling of one side of his tongue due to angioedema, emphasizing the need for quick recognition of this condition for effective treatment.
- * This case is noteworthy as it is one of the few documented instances in English literature and the first from Africa, pointing to the possibility of either its rarity or under-reporting in the region, where ACE inhibitors are frequently prescribed.
Acute Abdominal Pain as the Initial Presentation of an Acquired C1 Inhibitor Deficiency.
GE Port J Gastroenterol
August 2024
Allergy and Clinical Immunology Department, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Article Synopsis
- - Acquired angioedema (AAE) is a rare condition that can cause severe abdominal pain and is often misdiagnosed in emergency rooms, potentially leading to unnecessary treatments.
- - A case study of a 47-year-old man revealed that initial suspicion of ACEI-induced angioedema was incorrect; instead, tests showed AAE with abnormal C1 inhibitor function and low complement levels.
- - Recognizing AAE early in patients with acute abdominal symptoms is crucial, as it can indicate underlying serious conditions and lead to better treatment outcomes.
Angiotensin-Converting Enzyme Inhibitors and Other Medications Associated With Angioedema.
Cureus
November 2023
Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Article Synopsis
- * Histamine-mediated angioedema usually comes with allergic reactions such as itching and hives, while bradykinin-mediated cases may be hereditary and present more gastrointestinal symptoms without the itching.
- * Certain medications, especially ACE inhibitors for blood pressure, can increase the risk of angioedema, which can be severe; this overview covers the causes, symptoms, and treatment of drug-induced angioedema.
Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus.
J Allergy Clin Immunol
April 2024
Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany; Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, Germany. Electronic address:
Article Synopsis
- Angioedema is a serious reaction linked to ACE inhibitors, and its causes include genetic and non-genetic factors; recent studies have begun to uncover genetic risk factors but not the full underlying mechanisms.!* -
- Researchers analyzed data from over 1,000 European patients, discovering three significant genetic risk loci associated with ACEi-induced angioedema, one of which has not been previously noted.!* -
- The findings underscored the role of bradykinin signaling and coagulation pathways while suggesting new genetic candidates involved in angioedema, highlighting similar genetic effects in both European and African-American patients.!*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!